For the short term, lets take a look to stock behavior when the previous good news was released: "AEterna Zentaris Inc Granted Patent In U.S. For AEZS-130"(Aug 08). The stock went up 20% to pull back 15% in 3 days and then started again to rise for nearly a +100% (max, Sept 21).
It's better to be cautious this time as well and hold or buy below 2.50 as there is a strong possibility to see a nice rally in the next weeks, likely helped by a bullish market.
aezs108 is the possible home run, aezs130 small market, and peri worse than placebo in previous trial so i don't expect anything but failure from the peri trials, although they do keep people employed in the meantime i guess. all imo, do your own dd
I think peri is going to surprise us. Why would a company advertise discussing results 3 weeks prior to the actual presentation? They know the reaction will be positive.There is a lot going on here in the first quarter of 2013.At these prices aezs is a great investment. There is very little shorting of this stock.It has been being accumulated the past few weeks.Watch the pps steadily rise as we get closer to to the conference.
If you read the scientific literature, the 70+ bortezimib refractory/relapsed patients did better with perifosine/bortezimib than the bortezimib naive patients in the original bortezimib trials. Perifosine has a strong chance here, with real powered phase II data. The group they are working with (Richardson etc) really know what they are doing.